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Background: Pulsed electromagnetic field (PEMF) therapy has shown promising therapeutic 
effectiveness on bone- and cartilage-related pathologies, being also safe for management of 
knee osteoarthritis.
Aim: The aim of this study was to investigate the clinical efficacy of a PEMF device for 
management of knee osteoarthritis in elderly patients.
Materials and methods: A total of 33 patients were screened, and 28 patients, aged between 
60 and 83 and affected by bilateral knee osteoarthritis, were enrolled in this study. They received 
PEMF therapy on the right leg for a total of three 30-minute sessions per week for a period of 
6 weeks, while the left leg did not receive any treatment and served as control. An intravenous 
drip containing ketoprofen, sodium clodronate, glucosamine sulfate, calcitonin, and ascorbic 
acid, for a total volume of 500 mL, was administered during PEMF therapy. At baseline and 
3 months post-PEMF therapy, Visual Analog Scale (VAS) was used to assess knee pain and 
Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) was used to measure 
knee pain, stiffness and physical function.
Results: Changes in VAS and WOMAC scores were calculated for both knees as baseline minus 
post-treatment. A two sample Student’s t-test, comparing change in knee-related VAS pain for PEMF-
treated leg (49.8 ± 2.03) vs control leg (11 ± 1.1), showed a significant difference in favor of PEMF 
therapy (P , 0.001). A two sample Student’s t-test comparing change in knee-related WOMAC pain, 
stiffness, and physical function for PEMF-treated leg (8.5 ± 0.4, 3.5 ± 0.2, 38.5 ± 2.08, respectively) 
vs control leg (2.6 ± 0.2; 1.6 ± 0.1; 4.5 ± 0.5 respectively), also showed a significant difference in 
favor of PEMF therapy (P , 0.001). No adverse reactions to therapy were observed.
Conclusion: The present study shows that PEMF therapy improves pain, stiffness and physical 
function in elderly patients affected by knee osteoarthritis.
Keywords: osteoarthritis, elderly, pulsed electromagnetic field, magnet therapy, knee
Introduction
Osteoarthritis (OA) is a degenerative joint disease frequently affecting the knee and 
afflicting the constantly increasing elderly population.1,2 Knee OA symptoms include pain, 
stiffness, and functional limitation, leading to loss of autonomy and poor quality of life 
in patients affected by this disease.3 Nowadays, various treatment options are available 
for the management of this condition. They include: nonsteroidal anti-inflammatory 
drugs (NSAIDs) for pain management;4 bisphosphonates to decrease pain and improve 
functionality preserving the structural integrity of subchondral bone;5 therapeutic exercise;6 
viscosupplementation with hyaluronic acid alone or in combination with bisphosphonates or 
NSAIDs to improve pain and functional activity7–9 since hyaluronic acid improves articular 
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cartilage degeneration and decreases osteophyte formation, 
as showed by experimental studies using OA models.10,11 
These treatment modalities are effective in reducing pain and 
inflammation, but their long-term administration is associated 
with a high incidence of side effects or may not be applicable to 
the elderly.12 Building upon these foundations, there is an urgent 
need for alternative therapies for this pathological condition. 
Pulsed electromagnetic field (PEMF) therapy has proved to be 
safe and has also shown promising therapeutic effectiveness 
on bone- and cartilage-related pathologies, including knee and 
cervical spine OA.13–18
Aim
The aim of this study was to investigate the clinical efficacy 




A total of 33 patients were screened, and 28 patients, aged 
between 60 and 83 (69.9 ± 1.5 [mean ± Standard Error of 
the Mean {SEM}]) and affected by bilateral knee OA, were 
enrolled in this study. All patients signed the informed consent. 
The protocol was planned and applied in agreement with the 
Declaration of Helsinki and was approved by the Institutional 
Review Board at the Poliambulatorio del Secondo Parere 
(Modena, Italy), where the procedure was performed.
Inclusion/exclusion criteria
The inclusion criteria for this study were a diagnosis of bilateral 
knee OA according to the Diagnostic and Therapeutic Crite-
ria Committee of the American Rheumatism Association,19 
recurrent joint pain for at least a year prior to treatment, and 
daily pain in the knee $30 mm, as assessed by a 1–100 mm 
Visual Analog Scale (VAS). The exclusion criteria were: 
unilateral knee OA, intra-articular administration of drugs 
to the affected knees within 6 months before the study, sys-
temic corticosteroid therapy or physiotherapy (iontophoresis 
with anti-inflammatory drugs, soft [not heating] laser, and 
ultrasound therapy) in the previous 6 weeks, and knee pain 
due to malignant, autoimmune and inflammatory pathologies 
or resulting from defective pathologies of the knee.
Therapeutic regimen
PEMF therapy was performed using the Magnetofield device 
(F&B International, Parma, Italy). The applicators were held 
at the sides of the knee by a velcro band. The medical device 
combines low and high frequencies by means of 2 local 
devices in the shape of a hemisphere. The low-frequency 
field releases an intensity between 50 and 100 Gauss. The 
high-frequency field develops an intensity between 60 and 
80 decibel relative to 1 volt (dBV)/meter (m). Low frequency 
takes the form of a square wave with frequency comprised 
between 6 and 100 Hz and duty cycle comprised between 
30% and 70%. The high frequency also takes the form of a 
square wave, which is made up of a modulating and a car-
rier wave (continuous modulation). The modulating wave 
frequency varies between 100 and 5000 Hz, with duty cycle 
constant at 50%. The carrier-wave frequency varies between 
20 and 30 MHz, with duty cycle at 50%.
In the present study, the patients underwent two consecu-
tive therapeutic regimens: (1) 6÷100 Hz (low frequency) and 
500÷2000 Hz (high frequency) for 15 minutes, and (2) 6÷100 
Hz (low frequency) and 100÷5000 Hz (high frequency) for 
15 minutes. A total of three 30-minute sessions per week 
for a period of 6 weeks were administered to each patient. 
The right leg was treated with PEMF therapy, while the left 
leg did not receive any treatment and was used as control 
(Figure 1). An intravenous drip, containing ketoprofen (4 mL 
[160 mg/mL]; Dompè Farmaceutici, Milan, Italy), sodium 
Figure 1 Patient undergoing PEMF therapy (right leg).
Abbreviation: PEMF, pulsed electromagnetic field.





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Interventions in Aging 2013:8
clodronate (10 mL [30 mg/mL]; Abiogen Pharma, Pisa, 
Italy), glucosamine sulfate (1 mL [1.5 mg/mL]; Rottapharm, 
Monza, Italy), calcitonin (1 mL [100 Ui/mL]; Sandoz Indus-
trial Products, Trento, Italy), and ascorbic acid (5 mL [0.2 g/
mL]; Bayer, Milan, Italy), was administered while patients 
were receiving PEMF therapy.
Assessment of results
VAS and the Western Ontario McMaster Universities 
Osteoarthritis Index (WOMAC) have been extensively 
used in clinical investigations to assess pain, stiffness, and 
physical function in patients affected by knee OA.20–22 In 
our study, VAS (0–100 mm, 0 = no pain, 100 = maximum 
pain) and WOMAC (subscore 0–20, 0 = minimum pain, 
20 = maximum pain) were used to measure knee-related 
pain at baseline and at 3 months post-PEMF therapy. 
Furthermore, WOMAC was also used to determine knee-
related stiffness (subscore 0–8, 0 = minimum stiffness, 
8 = maximum stiffness) and physical function (subscore 
0–68, 0 = minimum physical function, 68 = maximum 
physical function).
Statistical analysis
All data are represented as the means ± SEM and were 
analyzed using GraphPad Prism 5.04 (GraphPad Software 
Inc., San Diego, CA, USA). Changes in VAS and WOMAC 
scores were calculated for both knees as baseline minus 
post-treatment. An unpaired two-sample Student’s t-test was 
used to compare change in knee-related VAS and WOMAC 
scores for PEMF-treated leg (mean ± SEM) vs control leg 
(mean ± SEM). P , 0.05 was considered significant.
Results
A total of 28 patients participated in the present study. At 
baseline, no significant difference was observed in mean 
VAS and WOMAC pain and mean WOMAC stiffness and 
physical function between left and right knee. VAS pain 
in the right knee changed from a baseline of 78.2 ± 1.2 
to 28.4 ± 1.2 mm at 3 month follow-up. VAS pain in the 
control knee changed from a baseline of 78.2 ± 1.9 to 
67.2 ± 1.7 mm at 3 month follow-up. In the right knee, 
WOMAC pain, stiffness, and physical function changed 
from baseline values of 15.6 ± 0.3, 6.3 ± 0.2, and 54.4 ± 1.8 
to 7.1 ± 0.3, 2.8 ± 0.1, and 15.8 ± 0.9 at 3 month follow-up, 
respectively. In the control knee, WOMAC pain, stiffness, 
and physical function changed from baseline values of 
15.3 ± 0.3, 6.3 ± 0.2, and 54.5 ± 1.8 to 12.9 ± 0.4, 4.7 ± 0.2, 
and 50.03 ± 1.8 at 3 month follow-up, respectively.
At 3 month follow-up, knee-related VAS pain signifi-
cantly improved in PEMF-treated leg (49.8 ± 2.03) if com-
pared with control leg (11 ± 1.1; P < 0.001, Figure 2). At 3 
month follow-up, knee-related WOMAC pain, stiffness, and 
Figure 2 Change in knee-related VAS pain for PEMF-treated leg vs control leg. Data 
are presented as the means ± SEM.
Note: ***P , 0.001.
Abbreviations: VAS, Visual Analog Scale; PEMF, pulsed electromagnetic field; SEM, 
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Control (left knee)
Figure 3 Change in knee-related WOMAC pain (A), stiffness (B), and physical function 
(C) for PEMF-treated leg vs control leg. Data are presented as the means ± SEM.
Note: ***P , 0.001.
Abbreviations: PEMF, pulsed electromagnetic field; SEM, Standard Error of the Mean; 
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physical function significantly improved in PEMF-treated 
leg (8.5 ± 0.4, 3.5 ± 0.2 and 38.5 ± 2.08, respec tively) if 
compared with control leg (2.6 ± 0.2, 1.6 ± 0.1 and 4.5 ± 0.5, 
 respectively; P < 0.001, Figure 3). No adverse reactions to 
therapy were observed.
Discussion
Experimental studies had previously shown that PEMF 
therapy produces an anabolic effect on the two key cell types 
in the skeletal system, ie, osteoblasts and chondrocytes23–26 that 
are involved in experimental and clinical OA. Furthermore, 
PEMF therapy possesses healing properties at the cellular 
level.27–31 In the present study we investigated the efficacy of 
PEMF therapy for management of knee OA-related pain, stiff-
ness and physical function in elderly patients. We observed a 
significant improvement in all the above mentioned endpoints 
at the 3-month follow-up in the knee receiving PEMF therapy, 
if compared to the control knee without adverse events. Previ-
ous studies show contrasting results on the efficacy of PEMF 
therapy in the management of knee OA-related symptoms. 
Positive results, consistent with a significant improvement in 
activities of daily living, stiffness and pain following PEMF 
therapy, were reported in 83 patients affected by knee OA, if 
compared with control subjects at 6- and 12-week follow-up 
following a 6-week therapy.32 This evidence was confirmed 
by another study involving 34 patients affected by early knee 
OA, who experienced a 50% decrease in VAS pain starting 
at day 1 and persisting up to day 42.33 Findings from Fischer 
and coworkers showed positive results in 71 knee OA patients 
who underwent low-frequency PEMF therapy for 6 weeks.34 
Patients had an increase in mobility and walking distance 
test, with long-term analgesic and functional effects even at 
4 weeks after the end of treatment.34 A significant improvement 
in WOMAC score was also observed in 75 patients affected 
by knee OA, who received a 6-week PEMF therapy.35
Trock and colleagues also reported an improvement in pain 
and functional performance in patients affected by knee OA 
undergoing PEMF therapy for about 1 month, if compared to 
control group.15 In opposition to the studies mentioned above, 
Ozgüçlü and coworkers performed a study involving 40 patients 
undergoing PEMF therapy for 2 weeks and found no differ-
ences between sham and treated group concerning WOMAC 
pain, stiffness, and physical function scores.36 Ay and Evcik 
observed a significant improvement in pain in 55 patients 
affected by knee OA after hot pack/therapeutic ultrasound/
PEMF therapy, but this improvement was also present in the 
sham group after five sessions per week for 2 weeks.37 In our 
study, we observed a slight decrease in VAS and WOMAC pain, 
stiffness, and physical function in the control knee likely due 
to the intravenous drip. Therefore, a therapy combining PEMF 
therapy and an intravenous drip containing ketoprofen, sodium 
clodronate, glucosamine sulfate, calcitonin and ascorbic acid 
may be helpful to provide increased and accelerated relief from 
knee OA-related symptoms.
Conclusion
PEMF therapy produces a significant benefit in terms of 
reduction in knee-related pain, stiffness, and physical func-
tion in elderly patients with knee OA. Further studies need 
to be designed to determine effectiveness of PEMF therapy 
in the long-term follow-up and clarify its mechanism.
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